KPV

KPV is a tripeptide (Lys-Pro-Val) representing the C-terminus of α-melanocyte stimulating hormone (α-MSH), where the main anti-inflammatory activity of the molecule is concentrated. Discovered by Anna Catania and James Lipton's group (Zurich/Chicago) in the 1990s during melanocortin system research. The mechanism is inhibition of the NF-κB signaling pathway and reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at the epithelial cell level, without activating melanocortin receptors (i.e. no pigmentation effects unlike Melanotan 2). Published studies document potential in inflammatory bowel disease (ulcerative colitis, Crohn's), atopic dermatitis and contact allergies. KPV's uniqueness is the possibility of oral and topical administration — the small molecular mass allows stability in the gastrointestinal tract, something rare for peptides. In dermatological research it is also applied in 0.01-0.1% creams. Storage: -20°C lyophilized, stable over 24 months.